Tecelra (afamitresgene autoleucel)
Adaptimmune Therapeutics · TCR-T Cell Therapy — MAGE-A4 Directed
What is Tecelra? Tecelra (afamitresgene autoleucel, afami-cel) is the first FDA-approved TCR-T cell therapy, indicated for HLA-A*02:01, 02:05, or 02:06 positive adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy.
About Tecelra
| Brand Name | Tecelra |
| Generic / INN | afamitresgene autoleucel |
| Drug Class | TCR-T Cell Therapy — MAGE-A4 Directed |
| Manufacturer | Adaptimmune Therapeutics |
| Administration | IV infusion (autologous, patient-specific) |
| FDA Approval | 2024 |
FDA-Approved Uses for Tecelra
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Unresectable or metastatic synovial sarcoma — HLA-A*02:01, 02:05, or 02:06 positive adult patients with MAGE-A4 positive tumors who received prior chemotherapy
How Does Tecelra Work?
Afami-cel consists of the patient's own T cells engineered to express a T-cell receptor (TCR) targeting MAGE-A4 — a cancer-testis antigen expressed in synovial sarcoma. Unlike CAR-T cells (which target surface proteins), TCR-T cells recognize intracellular antigen peptides presented on HLA molecules on cancer cells, enabling recognition and destruction of tumor cells displaying MAGE-A4/HLA-A*02 complexes.
Dosage & Administration
Single IV infusion following lymphodepleting chemotherapy (fludarabine + cyclophosphamide). Must be administered at certified healthcare facilities. Manufacturing takes approximately 6–8 weeks from T cell collection to infusion.
Warnings, Precautions & Side Effects
General Warning
Cytokine release syndrome (CRS). Immune effector cell-associated neurotoxicity syndrome (ICANS). Prolonged cytopenias. Serious infections. Secondary T-cell malignancies. Hemophagocytic lymphohistiocytosis (HLH). Available ONLY through the Tecelra REMS Program.
Common Side Effects
- CRS
- Prolonged cytopenias
- Infections
- Fatigue
- Edema
- Nausea
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Cryopreserved product stored at ≤ −130°C. Requires specialized cryogenic shipping and storage.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Tecelra is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Tecelra. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Tecelra
Tecelra (afamitresgene autoleucel) is the first approved TCR-T cell therapy. It uses the patient's T cells engineered with a TCR targeting MAGE-A4, approved for HLA-matched adults with unresectable/metastatic synovial sarcoma.
CAR-T cells use a synthetic receptor to target proteins on the surface of cancer cells. TCR-T cells use a natural T-cell receptor to target intracellular proteins (like MAGE-A4) that are presented on HLA molecules — allowing recognition of targets that cannot be reached by CAR-T approaches.
Two tests are required: HLA typing (must be HLA-A*02:01, 02:05, or 02:06 positive) AND MAGE-A4 expression testing on tumor tissue.
As a 2024 approval, coverage is evolving. Both biomarker tests and full prior authorization with documentation of prior chemotherapy are required. BiologicHealthPlus can assist with access coordination.
Related Medications & Conditions
Related Medications
Yescarta (CAR-T — CD19) · Abecma (CAR-T — BCMA) · Lifileucel (TIL therapy) · Doxorubicin (prior chemo for sarcoma)
Related Conditions
Synovial sarcoma · Soft tissue sarcoma · MAGE-A4 positive tumors